Opsumit and Uptravi defend Actelion's rare-disease portfolio and inspired J&J's pending acquisition.
Actelion has agreed to be purchased by J&J in an all-cash deal for $30 billion ($280/CHF 280 per share), far exceeding our stand-alone Actelion fair value estimate of CHF 112 per share. J&J expects this deal to improve long-term revenue growth rates by at least one percentage point and long-term earnings by 1.5-2 percentage points, which fits with our stand-alone Actelion estimates. With the deal expected to close in the second quarter, we are lowering our J&J fair value estimate fr...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.